Introduction
============

Aristolochic acid (AA) is a carcinogenic, mutagenic and nephrotoxic compound, which is commonly present in members of the plant family of Aristolochiaceae and is widely used in Chinese herbal medicine. Structurally, AA is related to nitrophenanthrene carboxylic acid, principally aristolochic acid I (AA-I) and aristolochic acid II (AA-II) ([@b1-mmr-12-05-6533]). Consumption or administration of AA or AA-containing plants leads to nephrotoxicity and carcinogenesis, resulting in chronic kidney disease ([@b2-mmr-12-05-6533]) and upper urinary tract carcinoma (UUC) ([@b3-mmr-12-05-6533]). Balkan endemic nephropathy (BEN) and Chinese Herb Nephropathy (CHN) share the same etiology ([@b4-mmr-12-05-6533]). Specifically, BEN is a chronic tubulointerstitial disease, affecting individuals living in the alluvial plains along the tributaries of the Danube River. BEN is closely associated with urothelial cell carcinoma of the upper urinary tract ([@b5-mmr-12-05-6533]). The etiology of BEN was hypothesized to be due to ingestion of a toxic component of Aristolochia in bread prepared from flour with contaminated grain ([@b6-mmr-12-05-6533]); however, due to the limitation of coeval methodology and technology, the etiology was not confirmed at that time and was unknown for \>50 years ([@b7-mmr-12-05-6533]). Another study suggested that Ochratoxin A (OTA) could be the cause of BEN due to the fact that individuals livings in regions where that had been an epidemic of BEN were exposed to relatively high OTA concentrations ([@b8-mmr-12-05-6533]); however, Clark and Snedeker ([@b9-mmr-12-05-6533]) demonstrated that high OTA levels in the blood and urine can occasionally be found in individuals not suffering from BEN ([@b9-mmr-12-05-6533]). An epidemiologic and experimental study conducted by Grollman and Jelaković ([@b10-mmr-12-05-6533]) denied the correlation between OTA and BEN, and instead demonstrated the presence of dA-aristolactam (AL) and dG-AL DNA adducts in the renal cortex of patients with BEN but not in patients with other chronic renal diseases using ([@b32-mmr-12-05-6533]) P-post labeling/PAGE and authentic standards ([@b11-mmr-12-05-6533]), which confirmed that AA is the cause of BEN. Furthermore, CHN gained attention in 1991 when nephrologists noticed an increase in the number of otherwise healthy females with different degrees of renal failure. These females all visited the same private clinic for weight control and had ingested extracts of Chinese herbs containing *Aristolochia fangchi* ([@b12-mmr-12-05-6533]), \~100 of these women developed chronic renal deficiency. Thereafter, Vanherweghem *et al* was the first to identify that the Chinese herbs were associated with chronic renal deficiency ([@b12-mmr-12-05-6533],[@b13-mmr-12-05-6533]). Cosyns *et al* suggested that AA is the most likely cause of the renal injury and later development of urothelial-cell atypia and carcinoma ([@b3-mmr-12-05-6533]). A number of studies also subsequently confirmed this hypothesis ([@b2-mmr-12-05-6533],[@b14-mmr-12-05-6533]--[@b16-mmr-12-05-6533]). Although AA is found primarily in members of the genus *Aristolochia*, it may be also present in other plant types ([@b17-mmr-12-05-6533]). AA binds to genomic DNA after metabolic activation and forms AL-DNA adducts, generating a unique TP53 mutational spectrum in the urothelium. The AL-DNA adducts are concentrated in the renal cortex, which could serve as a biomarker for AA exposure ([@b10-mmr-12-05-6533],[@b11-mmr-12-05-6533],[@b18-mmr-12-05-6533]). AA also specifically induces TP53 A:T→T:A mutation and is considered as the \'TP53 mutation signature\' of BEN and AAN-UUC ([@b18-mmr-12-05-6533],[@b19-mmr-12-05-6533]). However, the precise molecular mechanism underlying AA-induced BEN or UUC remains to be defined.

MicroRNAs (miRNAs) are a class of highly conserved small RNA molecules, which regulate key biological processes, including cell proliferation, differentiation, development and metabolism ([@b20-mmr-12-05-6533]). Dysregulation of miRNA expression contributes to human cancer development; for example, miRNAs regulate all hallmarks of cancer in cell growth, cell cycle control, apoptosis, tumor invasion, metastasis and angiogenesis ([@b21-mmr-12-05-6533],[@b22-mmr-12-05-6533]). Molecularly, miRNAs regulate the expression of various signal transduction pathway genes, such as transforming growth factor-β (TGFβ), WNT, Notch and epidermal growth factor (EGF) ([@b23-mmr-12-05-6533]). A previous study showed aberrant expression of miRNAs in kidney, bladder and prostate cancer ([@b24-mmr-12-05-6533]). Izquierdo *et al* ([@b25-mmr-12-05-6533]) reported a differential miRNA expression pattern between patients with progressing and non-progressing UUC. Clinically, patients with BEN and CHN have an apparent higher risk of developing UUC than the normal population. Therefore, the present study aimed to investigate whether there is any difference in miRNA expression between AAN-induced UUC and common UUC using miRNA microarray analysis. The results validated the differentially expressed miRNAs using reverse transcription-quantitative polymerase chain reaction (RT-qPCR).

Materials and methods
=====================

Patient samples
---------------

In the present study, paraffin-embedded tissue samples were collected from 20 patients with AA nephropathy (AAN-UUC) and 20 non-AAN-UUC patients, who had UUC but not associated with AA, treated in Shanghai Jiao Tong University-Affiliated First Hospital (Shanghai, China) between 2005 and 2010. All the patients were diagnosed according to medical history and pathology of tumor lesions. All the patients with AAN-UUC had a clear AA-containing drug intake history, and received cadaveric renal transplant between 2005 and 2010. Non-AAN-UUC patients did not have a history of AA contact, transplantation, and immunosuppressive drugs. Five samples from each group (AAN group, two males and three females; non-AAN group, four males and one female) were subjected to an miRNA microarray analysis and the rest of tissue samples (11 females and nine males in the AAN group, seven females and 13 males in the non-AAN group) were utilized as a set of samples for verification by RT-qPCR analysis. A protocol for the use of human surgical samples was approved by the Medical Ethics Committee of Shanghai First People\'s Hospital of Shanghai Jiao Tong University and each participant signed a written consent form for using their data in the present study. The patients were aged between 52 and 78 years.

miRNA microarray analysis
-------------------------

The miRNA microarray profiling was performed using Affymetrix GeneChip miRNA arrays (Affymetrix, Inc., Santa Clara, CA, USA) according to the manufacturer\'s instructions. Briefly, 1 *µ*g of total RNA was labeled by polyA polymerase addition using the Genisphere FlashTag HSR kit according to the manufacturer\'s instructions (Genisphere, Hatfield, PA, USA). The labeled RNA was hybridized as a probe to the Affymetrix miRNA array, according to the manufacturer\'s details. Standard Affymetrix array cassette staining, washing and scanning was performed using the post-hybridization kit (cat. no. 900720; Affymetrix) and GeneChip Scanner 3000 (Affymetrix, Inc.). Feature extraction was performed using Affymetrix Command Console software (v.1.2). The raw data were treated by the following workflow: Background detection, RMA global background correlation, quartile normalization, median polish and log2-transformation with miRNA QC tool software (Affymetrix).

Gene ontology (GO) and gene pathway analyses
--------------------------------------------

The gene GO analysis was performed to evaluate differential expression. Pathway analysis was used to sort out the significant pathways of the differential genes according to KEGG, Biocarta and Reatome ([@b26-mmr-12-05-6533]--[@b28-mmr-12-05-6533]).

RNA isolation and RT-qPCR
-------------------------

Total cellular RNA was isolated from tissue samples and subjected to RT-qPCR analysis using an ABI 7900 HT Real-time PCR system in a 384-well plate format (cat. no. 4366596; Applied Biosystems, Foster City, CA, USA). Reverse transcription was performed, according to the manufacturer\'s instructions. Brifely, 1 *µ*g RNA was reverse-transcribed into cDNA using a stem-loop RT primer. The reaction conditions were as follows: 16 °C for 30 min, 42°C for 30 min and 85°C for 5 min. RNA was isolated from all samples using an mirVanaTM miRNA Isolation kit (cat. no. AM1560; Ambion Life Technologies, Foster City, CA, USA), according to the manufacturer\'s instructions. The PCR reaction volume of 5 *µ*l contained 2.5 *µ*l TaqMan PCR Master Mix-UNG (2X), 0.25 *µ*l each TaqMan assay probe (20X), 1.25 *µ*l of diluted cDNA and 1 *µ*l H~2~O. qPCR was performed at 95°C for 10 min, followed by 40 cycles of 95°C for 15 sec and 60°C for 1 min using the specific miRNA primers ([Table I](#tI-mmr-12-05-6533){ref-type="table"}). The data were analyzed using ABI RQ Manager software (Applied Biosystems) after exportation as a SDS file.

Statistical analysis
--------------------

An random variance model t-test was performed to analyze the microarray data by comparing the differentially expressed genes between the control and experimental group ([@b29-mmr-12-05-6533]--[@b31-mmr-12-05-6533]). The two-side Fisher\'s exact test was used to analyze the GO category data and the false discovery rate (FDR) was used to calculate the P-value as mentioned by Dupuy *et al* ([@b32-mmr-12-05-6533]). The smaller the FDR, the lower the error in judgment of the P-value. The FDR was defined, according to the following equation: $$FDR = 1 - \frac{N_{k}}{T}$$

N*~k~* refers to the number of Fisher\'s test P-values that were below the χ^2^ test P-values ([@b32-mmr-12-05-6533]). T refers tot he total number of tests. The χ^2^ test was used to evaluate patient characteristics (IBM SPSS version 19, IBM, Armonk, NY, USA). The unpaired 2-tailed Student\'s t-test was used to evaluate the association between miRNA expression and clinicopathological data from the tumor stage/size. The statistical analyses were performed either by SPSS software or Graphpad Prism 5 (Graphpad Software, Inc., San Diego, CA, USA).

Results
=======

Characteristics of patients with UUC
------------------------------------

A total of 20 samples each from patients with AAN-UUC and non-AAN-UUC were collected for miRNA microarray profiling of differentially expressed miRNAs. The clinical characteristics of these patients are listed in [Table II](#tII-mmr-12-05-6533){ref-type="table"}. Specifically, all the patients with AAN-UUC had clear AA-containing drug intake history, and received cadaveric renal transplant between 2005 and 2010. A standard immunosuppressive regimen was administered to these patients, which included cyclosporine A, mycophenolate mofetil and prednisone with or without anti-lymphocyte antibody-induction therapy. All the enrolled patients were diagnosed with UUC during the follow-up, according to symptoms, including hematuria and pain, and CT scanning. Whereas, non-AAN-UUC patients had no history of contact with AA and did not undergo transplantation.

Differential expression of miRNAs in AAN-UUC tissues
----------------------------------------------------

The differential expression of miRNAs was profiled in AAN-UUC tissues using miRNA microarray analysis of five samples of AAN and non-AAN UUC tissues. The 29 most differentially expressed miRNAs were identified between AAN-UUC and non-AAN-UUC tissues (FDR\<0.05, P\<0.05; [Table III](#tIII-mmr-12-05-6533){ref-type="table"} and [Fig. 1](#f1-mmr-12-05-6533){ref-type="fig"}). In [Fig. 1](#f1-mmr-12-05-6533){ref-type="fig"}, a heat map is shown for the eight most significant differentially expressed miRNAs using GeneChip 3.0; each column represents a tissue sample, and each row represents an miRNA. The dendrograms of clustering analysis for samples and miRNAs are displayed on the top and left, respectively. Signals 1--5 represent AAN-UUC samples and signals 6--10 represent non-AAN-UUC tissue samples. Furthermore, TargetScan analyses were performed to predict the functions and targeted genes of these differentially expressed miRNAs. It was found that the mTOR, MAPK, focal adhesion, long-term potentiation and protein processing in endoplasmic signaling pathways were upregulated, whereas PI3K-Akt, HTLV-I infection, and the proteoglycan pathways were downregulated ([Fig. 2](#f2-mmr-12-05-6533){ref-type="fig"}). Among upregulated genes, VEGFA, RPS6KA6, IGF1, RPS6KA3 and FGFR3 were frequently upregulated in UUC tissues, whereas E2F3, FGFR1, IGF1R, AR and RAS were down-regulated ([Table IV](#tIV-mmr-12-05-6533){ref-type="table"} and [Table V](#tV-mmr-12-05-6533){ref-type="table"}).

To further validate the microarray results, the eight genes with the greatest difference in expression compared with the non-AAN-UUC samples (P\<0.05; hsa-miR-488-3p, hsa-miR-4434, hsa-miR-4274, hsa-miR-4795-5p, hsa-miR-4784, hsa-miR-330-3p, hsa-miR-3916 and hsa-miR-181c-5p) were analyzed using qPCR. As a result, only expression of miR-488 and miR-181c was found to be significantly different (P\<0.05; [Fig. 3](#f3-mmr-12-05-6533){ref-type="fig"}).

Furthermore, the expression of miR-488 was higher in stage I and II than stage III and IV tumors (mean ± standard error, P= 0.038; [Fig. 4](#f4-mmr-12-05-6533){ref-type="fig"}), while miR-181c was highly expressed in tumors \>3 cm than in those \<3 cm (mean ± standard error, P=0.049; [Fig. 5](#f5-mmr-12-05-6533){ref-type="fig"}). However, these results in patients with non-AAN-UUC (P=0.207 and 0.127, respectively) were not validated. In addition, no other correlation was identified between miRNA expression and tumor behavior or prognosis.

Discussion
==========

In the present study, the expression of miRNAs in AAN-UUC tissues was compared with that in the non-AAN-UUC tissues in order to identify the unique gene alterations for AAN-UUC in order to improve the understanding of this pathogenesis. The 29 most differentially expressed miRNAs were revealed between AAN-UUC and non-AAN-UUC tissues, which could regulate the most frequently altered genes in AAN-UUC, such as VEGFA, RPS6KA6, IGF1, RPS6KA3, FGFR3, E2F3, FGFR1, IGF1R, AR and RAS. As, miRNAs can regulate cellular growth, cell cycle control, apoptosis, invasion, metastasis, tumor angiogenesis ([@b22-mmr-12-05-6533]) and carcinogenesis ([@b33-mmr-12-05-6533]), their expression may be important in AAN-UUC development.

The present study used formalin-fixed and paraffin embedded (FFPE) tissue samples for miRNA microarray and RT-qPCR analyses. To date, there is no specific AAN-UUC-derived cell line available commercially. However, the FFPE tissue samples, are the most widely available clinical specimens for histological and pathological analysis ([@b34-mmr-12-05-6533]), but contain fragmented nucleic acids. miRNA molecules are less prone to degradation for miRNA analysis in contrast to mRNA. Leite *et al* ([@b35-mmr-12-05-6533]) demonstrated non-significant differences in miRNA expression between FFPE and fresh tissue samples. Moreover, qPCR is considered a gold standard for quantification of gene expression and has been widely employed as a validation method for microarray studies ([@b36-mmr-12-05-6533]). Thus, the present study demonstrated novel and reliable results, however, these are preliminary data and more in depth studies are required to understand the role of miRNA in the pathogenesis of AAN-UUC. In this regard, we aim to validate the current data by collecting more fresh AAN-UUC tissues and generate a primary cell culture to investigate how these miRNAs are altered and involved in the regulation of tumor cell growth, apoptosis, invasion, metastasis and angiogenesis.

In the present miRNA microarray study, the most down-regulated miRNAs were hsa-miR-4795-5p, hsa-miR-4784, hsa-miR-330-3p, hsa-miR-15a-5p, hsa-miR-10a-5p, hsa-miR-181c and hsa-miR-200c-3p, whereas the most upregulated miRNAs were hsa-miR-488-3p, hsa-miR-4434, hsa-miR-4274 and hsa-miR-224-3p. These miRNAs were previously reported to be associated with the development and progression of different types of human cancer ([@b37-mmr-12-05-6533]--[@b39-mmr-12-05-6533]). For example, 5-fluorouracil treatment upregulated miR-4795-5p in nasopharyngeal carcinoma cell lines ([@b37-mmr-12-05-6533]). In addition, miR-4795-5p is also downregulated in stage II colorectal cancer ([@b38-mmr-12-05-6533]). Similarly, miR-200c expression was found to be lost in pancreatic cancer, and patients with high levels of miR-200c expression had significantly longer survival rates than those with low levels ([@b39-mmr-12-05-6533]). Expression of miR-200c has also been shown to be associated with upregulation of the expression of E-cadherin and downregulation of ZEB1 and ZEB2 in bladder cancer cell-lines ([@b39-mmr-12-05-6533]--[@b41-mmr-12-05-6533]). In addition, miR-181c was also shown to be highly expressed in gastric cancer tissues compared with gastric ulcer and chronic gastritis tissues ([@b42-mmr-12-05-6533]). By contrast, the present study showed that miR-488-3p was upregulated in AAN-UUC compared with non-ANN-UUC tissues. However, in the majority of published studies ([@b40-mmr-12-05-6533],[@b41-mmr-12-05-6533]), miR-488-3p was downregulated in different types of human cancer. miR-488 is able to inhibit the expression of androgen receptor (AR) in prostate cancer cells ([@b40-mmr-12-05-6533]). Sikand *et al* ([@b43-mmr-12-05-6533]) showed that overexpression of miR-488 downregulated the transcriptional activity of AR and inhibited the endogenous AR protein production in androgen-dependent and androgen-independent prostate cancer cells. Moreover, a study by Li *et al* ([@b44-mmr-12-05-6533]) demonstrated that suppression of miR-448 expression induced epithelial-mesenchymal transition by directly targeting SATB1 mRNA, and the latter promoter could be bound by activated NF-κB. It is unknown why this discrepancy occurred, however, it may be due to high levels of miR-488-3p expression in non-AAN-UUC compared with that of AAN-UUC tissues. Further investigation using larger sample sizes is therefore required to confirm these results. Meng *et al* ([@b45-mmr-12-05-6533]) recently published a study showing the effects of miR-21 and miR-34a levels in an AA-induced rat model; however, these two miRNAs were not identified in the present study. The discrepancy may be due to the differences in the nature of the design of the studies as Meng *et al* conducted an *in vitro* study and the present study was *ex vivo*.

Cancer is a group of human diseases with various heterogeneity, which could limit the reproducibility of changes in microRNA expression profiles; even the same tumor lesion may have different gene alterations. For instance, in bladder cancers, low-grade tumors exhibited downregulation of numerous miRNAs, and the most downregulated were miRs-99a/100, which were demonstrated to target FGFR3. Accoring to the literature, high-grade bladder cancer often exhibits upregulated levels of miR-21, and miR-21 can target P53. High-grade bladder cancer is characterized by marked miRNA upregulation ([@b46-mmr-12-05-6533],[@b47-mmr-12-05-6533]), whereas low-grade bladder cancer often exhibits miRNA downregulation. Compared with non-AAN-UUC, AAN-UUC has a distinctive gene alteration pattern, such as AL-DNA adducts and a unique TP53 mutational spectrum A:T→T:A, which implies the presence of a distinctive pathway. Following metabolic activation, AA reacts with genomic DNA to form AL-DNA adducts that generate a unique TP53 mutational spectrum in the urothelium (A:T→T:A). Transcription factor p53 protein is a tumor suppressor. It is the most commonly mutated gene in human cancer and is associated with the alteration of cellular bioactivity ([@b48-mmr-12-05-6533]). p53 protein not only regulates the expression of miRNAs, but is also a target of these miRNAs. For example, miR-34, miR-200 family, miR-192 family, miR-107, miR-145, miR-15a, and miR-16-1 have been identified to be modulated by p53; while miR-504, miR-33, miR-125b, miR-1285 and miR-380-5p have been reported to directly target p53 ([@b49-mmr-12-05-6533]).

Certain classical Aristolochic herbs, such as fangchi and mutong have been banned in a number of countries ([@b17-mmr-12-05-6533],[@b50-mmr-12-05-6533]). However, AA intake still occurs via contaminated grain in some Balkan regions. Moreover, certain AA-containing herbs could still be used due to lack of recognition ([@b17-mmr-12-05-6533]). Species of *Aristolochia* are widely distributed worldwide, with the exception if Australia, where only few species are known. Since ethnobotanical investigations have indicated that AA family members are frequently used in traditional medicine, it is likely that certain individuals take AA-containing herbs or combinations without being aware of it ([@b4-mmr-12-05-6533]). Furthermore, due to the prevalence of Chinese traditional medicine in China and other Asian countries, these herbal remedies are readily available via the internet. A survey conducted in Taiwan ([@b51-mmr-12-05-6533]) showed that approximately one-third of the population of Taiwan has been exposed to herbs containing AA. In traditional Chinese medicine, a phenomenon termed the \'Jun-Chen-Zou-Shi\' principle entails constructing a remedial herbal formula to mitigate the toxicity of the main ingredient. Recently Tsai *et al* ([@b52-mmr-12-05-6533]) performed metabolic analysis using ^1^H-NMR spectroscopy to validate whether Bu-Fei-A-Jiao-Tang, a compound remedy based on this principle, could decrease the toxicity of AA-containing herbs; however, the result did not support this claim. Thus, the function of the Jun-Chen-Zou-Shi principle was not able to ensure a reduction in AA nephrotoxicity. Despite increasing control of the use of AA by different countries, it is still accessible in numerous ways.

In conclusion, the current study showed that AAN-UUC may have unique miRNA alterations compared with non-AAN-UUC. Further studies using larger sample sizes are proposed to better understand the molecular mechanism underlying AAN-UUC development.
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###### 

GO analysis of gene pathways that may be regulated by differentially expressed miRNAs in aristolochic acid-induced upper urinary tract carcinoma.tissues. (A) Upregulated gene pathways. (B) Downregulated gene pathways. GO, gene ontology; AAN, aristolochic acid; UUC, upper urinary tract carcinoma.
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![Reverse transcription-quantitative polymerase chain reaction confirmation of differentially expressed miRNAs analyzed by the miRNA microarray between AAN-UUC and non-AAN-UUC tissue samples. miRNA, microRNA; AAN, aristolochic acid; UUC upper urinary tract carcinoma.](MMR-12-05-6533-g03){#f3-mmr-12-05-6533}

![Differential expression of miR-488 in early vs. late tumor stages. (A) AAN-UUC and (B) non-AAN-UCC. miRNA, microRNA; AAN, aristolochic acid; UUC upper urinary tract carcinoma.](MMR-12-05-6533-g04){#f4-mmr-12-05-6533}

![Differential expression of miR-181c in small vs. large tumors. (A) AAN-UUC and (B) non-AAN-UCC. miRNA, microRNA; AAN, aristolochic acid; UUC upper urinary tract carcinoma.](MMR-12-05-6533-g05){#f5-mmr-12-05-6533}

###### 

MicroRNA kits used for reverse transcription-quantitative polymerase chain reaction.

  Assay ID          Target sequence              Assay name
  ----------------- ---------------------------- -----------------
  463364_mat        AGAAGUGGCUAAUAAUAUUGA        hsa-miR-4795-5p
  002357            UUGAAAGGCUAUUUCUUGGUC        hsa-miR-488
  463501_mat        UGAGGAGAUGCUGGGACUGA         hsa-miR-4784
  000544            GCAAAGCACACGGCCUGCAGAGA      hsa-miR-330
  464679_mat        AAGAGGAAGAAAUGGCUGGUUCUCAG   hsa-miR-3916
  243075_mat        CAGCAGUCCCUCCCCCUG           hsa-miR-4274
  000482            AACAUUCAACCUGUCGGUGAGU       hsa-miR-181c
  Customer design   AGGAGAAGUAAAGUAGAA           has-miR-4434

###### 

Characteristics of patients with UUC.

  Clinicopathological feature   AAN-UUC N   Non-AAN-UUC N   P-value
  ----------------------------- ----------- --------------- ---------
  Age (mean ± SEM)              63.9±1.64   65.6±1.66       0.497
  Gender                                                    0.341
   Male                         9           13              
   Female                       11          7               
  Tumor differentiation                                     0.240
   Well                         4           9               
   Moderate                     7           5               
   Poor                         9           6               
  Tumor stage                                               0.519
   I--II                        9           7               
   III--IV                      11          13              
  Lymph node metastasis                                     0.465
   Yes                          4           6               
   No                           16          14              
  Distant metastasis                                        N/A
   Yes                          0           0               
   No                           20          20              
  Tumor size (cm)                                           0.057
   \<3                          14          8               
   \>3                          6           12              

AAN, aristolochic acid; UUC, upper urinary tract carcinoma; SEM, standard error of the mean.

###### 

Differential expression of microRNAs between AAN-UUC and non-AAN-UUC using miRNA microarray profiling analysis.

  Name of miRNA     P-value     FDR      GMI (AAN-UUC)   GMI (UUC)   Fold-change   Change
  ----------------- ----------- -------- --------------- ----------- ------------- --------
  hsa-miR-488-3p    0.0202204   \<0.05   2.75            1.91        1.44          Up
  hsa-miR-4434      0.0236167   \<0.05   1.96            1.41        1.39          Up
  hsa-miR-4274      0.0435406   \<0.05   4.12            2.91        1.42          Up
  hsa-miR-224-3p    0.0511639   \<0.05   5.46            3.24        1.68          Up
  hsa-miR-548x-3p   0.0578456   \<0.05   4.26            3.8         1.12          Up
  hsa-miR-890       0.0726481   \<0.05   3.6             2.32        1.55          Up
  hsa-miR-452-5p    0.0822436   \<0.05   4.98            3.17        1.57          Up
  hsa-miR-1272      0.0857332   \<0.05   4.34            3.2         1.35          Up
  hsa-miR-1294      0.1048154   \<0.05   3.51            2.58        1.36          Up
  hsa-miR-32-5p     0.1187305   \<0.05   3.09            2.34        1.32          Up
  hsa-miR-3910      0.1374783   \<0.05   4.89            3.76        1.3           Up
  hsa-miR-4795-5p   0.0064733   \<0.05   1.29            1.74        0.74          Down
  hsa-miR-4784      0.0231033   \<0.05   2.8             3.29        0.85          Down
  hsa-miR-330-3p    0.0280638   \<0.05   4.52            5.66        0.8           Down
  hsa-miR-3916      0.0409906   \<0.05   3.62            4.79        0.76          Down
  hsa-miR-181c-5p   0.047703    \<0.05   3.65            5.17        0.71          Down
  hsa-miR-342-5p    0.0551755   \<0.05   5.43            6.75        0.8           Down
  hsa-miR-4736      0.0581968   \<0.05   1.73            2.58        0.67          Down
  hsa-miR-15a-5p    0.0679372   \<0.05   7.75            8.59        0.9           Down
  hsa-miR-10a-5p    0.0930021   \<0.05   7.33            8.93        0.82          Down
  hsa-miR-4310      0.0981875   \<0.05   2.18            3.12        0.7           Down
  hsa-miR-4647      0.0987192   \<0.05   2.43            3.11        0.78          Down
  hsa-miR-4490      0.100964    \<0.05   4.24            3.18        1.33          Down
  hsa-miR-4695-3p   0.1017726   \<0.05   3.14            4.13        0.76          Down
  hsa-miR-3607-5p   0.1307393   \<0.05   4.52            5.97        0.76          Down
  hsa-miR-875-3p    0.1310434   \<0.05   1.7             2.2         0.77          Down
  hsa-miR-4499      0.1325093   \<0.05   2.87            3.71        0.77          Down
  hsa-miR-200c-3p   0.1352006   \<0.05   13.34           14.01       0.95          Down
  hsa-miR-3064-5p   0.1389973   \<0.05   2.24            2.89        0.77          Down

GMI (AAN-UUC), geom mean of intensities in the AAN-UUC group; GMI (UUC), geom mean of intensities in the non-AAN-UUC group; FDR, false discovery rate; AAN, aristolochic acid; UUC, upper urinary tract carcinoma.

###### 

Upregulated genes by altered microRNAs in AAN-UUC tissues.

  Path ID   Pathway name                                  Enrichment   P-value    FDR        Gene ID   Gene name
  --------- --------------------------------------------- ------------ ---------- ---------- --------- ------------
  04150     mTOR signaling pathway                        18.279       3.94E-06   3.75E-04   7422      VEGFA
  04150     mTOR signaling pathway                        18.279       3.94E-06   3.75E-04   27330     RPS6KA6
  04150     mTOR signaling pathway                        18.279       3.94E-06   3.75E-04   3479      IGF1
  04150     mTOR signaling pathway                        18.279       3.94E-06   3.75E-04   6197      RPS6KA3
  04150     mTOR signaling pathway                        18.279       3.94E-06   3.75E-04   1975      EIF4B
  04150     mTOR signaling pathway                        18.279       3.94E-06   3.75E-04   7248      TSC1
  04010     MAPK signaling pathway                        7.030        7.89E-06   3.75E-04   5908      RAP1B
  04010     MAPK signaling pathway                        7.030        7.89E-06   3.75E-04   5923      RASGRF1
  04010     MAPK signaling pathway                        7.030        7.89E-06   3.75E-04   6197      RPS6KA3
  04010     MAPK signaling pathway                        7.030        7.89E-06   3.75E-04   5906      RAP1A
  04010     MAPK signaling pathway                        7.030        7.89E-06   3.75E-04   2261      FGFR3
  04010     MAPK signaling pathway                        7.030        7.89E-06   3.75E-04   27330     RPS6KA6
  04010     MAPK signaling pathway                        7.030        7.89E-06   3.75E-04   9693      RAPGEF2
  04010     MAPK signaling pathway                        7.030        7.89E-06   3.75E-04   2122      MECOM
  04010     MAPK signaling pathway                        7.030        7.89E-06   3.75E-04   5534      PPP3R1
  04010     MAPK signaling pathway                        7.030        7.89E-06   3.75E-04   5601      MAPK9
  04510     Focal adhesion                                7.986        9.16E-06   3.75E-04   5908      RAP1B
  04510     Focal adhesion                                7.986        9.16E-06   3.75E-04   5923      RASGRF1
  04510     Focal adhesion                                7.986        9.16E-06   3.75E-04   5601      MAPK9
  04510     Focal adhesion                                7.986        9.16E-06   3.75E-04   5906      RAP1A
  04510     Focal adhesion                                7.986        9.16E-06   3.75E-04   7422      VEGFA
  04510     Focal adhesion                                7.986        9.16E-06   3.75E-04   3680      ITGA9
  04510     Focal adhesion                                7.986        9.16E-06   3.75E-04   4660      PPP1R12B
  04510     Focal adhesion                                7.986        9.16E-06   3.75E-04   2335      FN1
  04510     Focal adhesion                                7.986        9.16E-06   3.75E-04   3479      IGF1
  04720     Long-term potentiation                        15.447       1.07E-05   3.75E-04   5906      RAP1A
  04720     Long-term potentiation                        15.447       1.07E-05   3.75E-04   5908      RAP1B
  04720     Long-term potentiation                        15.447       1.07E-05   3.75E-04   6197      RPS6KA3
  04720     Long-term potentiation                        15.447       1.07E-05   3.75E-04   4660      PPP1R12B
  04720     Long-term potentiation                        15.447       1.07E-05   3.75E-04   5534      PPP3R1
  04720     Long-term potentiation                        15.447       1.07E-05   3.75E-04   27330     RPS6KA6
  04141     Protein processing in endoplasmic reticulum   7.662        1.62E-04   4.53E-03   1965      EIF2S1
  04141     Protein processing in endoplasmic reticulum   7.662        1.62E-04   4.53E-03   11231     SEC63
  04141     Protein processing in endoplasmic reticulum   7.662        1.62E-04   4.53E-03   27248     ERLEC1
  04141     Protein processing in endoplasmic reticulum   7.662        1.62E-04   4.53E-03   5601      MAPK9
  04141     Protein processing in endoplasmic reticulum   7.662        1.62E-04   4.53E-03   10130     PDIA6
  04141     Protein processing in endoplasmic reticulum   7.662        1.62E-04   4.53E-03   4287      ATXN3
  04141     Protein processing in endoplasmic reticulum   7.662        1.62E-04   4.53E-03   7322      UBE2D2
  04722     Neurotrophin signaling pathway                9.139        2.19E-04   5.10E-03   5906      RAP1A
  04722     Neurotrophin signaling pathway                9.139        2.19E-04   5.10E-03   6197      RPS6KA3
  04722     Neurotrophin signaling pathway                9.139        2.19E-04   5.10E-03   5601      MAPK9
  04722     Neurotrophin signaling pathway                9.139        2.19E-04   5.10E-03   5663      PSEN1
  04722     Neurotrophin signaling pathway                9.139        2.19E-04   5.10E-03   5908      RAP1B
  04722     Neurotrophin signaling pathway                9.139        2.19E-04   5.10E-03   27330     RPS6KA6
  04914     Progesterone-mediated oocyte maturation       10.627       4.56E-04   9.13E-03   27330     RPS6KA6
  04914     Progesterone-mediated oocyte maturation       10.627       4.56E-04   9.13E-03   2771      GNAI2
  04914     Progesterone-mediated oocyte maturation       10.627       4.56E-04   9.13E-03   3479      IGF1
  04914     Progesterone-mediated oocyte maturation       10.627       4.56E-04   9.13E-03   6197      RPS6KA3
  04914     Progesterone-mediated oocyte maturation       10.627       4.56E-04   9.13E-03   5601      MAPK9
  04340     Hedgehog pathway                              14.336       7.14E-04   1.25E-02   53944     CSNK1G1
  04340     Hedgehog pathway                              14.336       7.14E-04   1.25E-02   5727      PTCH1
  04340     Hedgehog pathway                              14.336       7.14E-04   1.25E-02   8945      BTRC
  04340     Hedgehog pathway                              14.336       7.14E-04   1.25E-02   51715     RAB23
  04723     Retrograde endocannabinoid signaling          8.873        1.06E-03   1.66E-02   57030     SLC17A7
  04723     Retrograde endocannabinoid signaling          8.873        1.06E-03   1.66E-02   5601      MAPK9
  04723     Retrograde endocannabinoid signaling          8.873        1.06E-03   1.66E-02   2771      GNAI2
  04723     Retrograde endocannabinoid signaling          8.873        1.06E-03   1.66E-02   2892      GRIA3
  04723     Retrograde endocannabinoid signaling          8.873        1.06E-03   1.66E-02   222236    NAPEPLD
  04114     Oocyte meiosis                                8.160        1.57E-03   2.19E-02   27330     RPS6KA6
  04114     Oocyte meiosis                                8.160        1.57E-03   2.19E-02   8945      BTRC
  04114     Oocyte meiosis                                8.160        1.57E-03   2.19E-02   3479      IGF1
  04114     Oocyte meiosis                                8.160        1.57E-03   2.19E-02   6197      RPS6KA3
  04114     Oocyte meiosis                                8.160        1.57E-03   2.19E-02   5534      PPP3R1
  05200     Pathways in cancer                            4.472        1.91E-03   2.43E-02   2261      FGFR3
  05200     Pathways in cancer                            4.472        1.91E-03   2.43E-02   2335      FN1
  05200     Pathways in cancer                            4.472        1.91E-03   2.43E-02   7422      VEGFA
  05200     Pathways in cancer                            4.472        1.91E-03   2.43E-02   5727      PTCH1
  05200     Pathways in cancer                            4.472        1.91E-03   2.43E-02   2122      MECOM
  05200     Pathways in cancer                            4.472        1.91E-03   2.43E-02   3479      IGF1
  05200     Pathways in cancer                            4.472        1.91E-03   2.43E-02   4824      NKX3-1
  05200     Pathways in cancer                            4.472        1.91E-03   2.43E-02   5601      MAPK9
  05031     Amphetamine addiction                         10.445       2.41E-03   2.82E-02   9586      CREB5
  05031     Amphetamine addiction                         10.445       2.41E-03   2.82E-02   5534      PPP3R1
  05031     Amphetamine addiction                         10.445       2.41E-03   2.82E-02   2892      GRIA3
  05031     Amphetamine addiction                         10.445       2.41E-03   2.82E-02   6571      SLC18A2
  04151     PI3K-Akt signaling pathway                    4.214        2.81E-03   3.03E-02   3479      IGF1
  04151     PI3K-Akt signaling pathway                    4.214        2.81E-03   3.03E-02   3680      ITGA9
  04151     PI3K-Akt signaling pathway                    4.214        2.81E-03   3.03E-02   7248      TSC1
  04151     PI3K-Akt signaling pathway                    4.214        2.81E-03   3.03E-02   2335      FN1
  04151     PI3K-Akt signaling pathway                    4.214        2.81E-03   3.03E-02   2261      FGFR3
  04151     PI3K-Akt signaling pathway                    4.214        2.81E-03   3.03E-02   9586      CREB5
  04151     PI3K-Akt signaling pathway                    4.214        2.81E-03   3.03E-02   7422      VEGFA
  04151     PI3K-Akt signaling pathway                    4.214        2.81E-03   3.03E-02   1975      EIF4B
  04728     Dopaminergic synapse                          6.977        3.20E-03   3.20E-02   2771      GNAI2
  04728     Dopaminergic synapse                          6.977        3.20E-03   3.20E-02   5601      MAPK9
  04728     Dopaminergic synapse                          6.977        3.20E-03   3.20E-02   9586      CREB5
  04728     Dopaminergic synapse                          6.977        3.20E-03   3.20E-02   2892      GRIA3
  04728     Dopaminergic synapse                          6.977        3.20E-03   3.20E-02   6571      SLC18A2
  04144     Endocytosis                                   5.376        3.81E-03   3.54E-02   2261      FGFR3
  04144     Endocytosis                                   5.376        3.81E-03   3.54E-02   9525      VPS4B
  04144     Endocytosis                                   5.376        3.81E-03   3.54E-02   9135      RABEP1
  04144     Endocytosis                                   5.376        3.81E-03   3.54E-02   26052     DNM3
  04144     Endocytosis                                   5.376        3.81E-03   3.54E-02   80223     RAB1-1FIP1
  04144     Endocytosis                                   5.376        3.81E-03   3.54E-02   8027      STAM
  04130     SNARE interactions in vesicular transport     15.232       4.04E-03   3.54E-02   9527      GOSR1
  04130     SNARE interactions in vesicular transport     15.232       4.04E-03   3.54E-02   8417      STX7
  04130     SNARE interactions in vesicular transport     15.232       4.04E-03   3.54E-02   8674      VAMP4
  00565     Ether lipid metabolism                        13.056       6.34E-03   5.11E-02   85465     EPT1
  00565     Ether lipid metabolism                        13.056       6.34E-03   5.11E-02   5048      PAFA-H1B1
  00565     Ether lipid metabolism                        13.056       6.34E-03   5.11E-02   8613      PPAP2B
  05205     Proteoglycans in cancer                       4.831        6.56E-03   5.11E-02   7422      VEGFA
  05205     Proteoglycans in cancer                       4.831        6.56E-03   5.11E-02   5727      PTCH1
  05205     Proteoglycans in cancer                       4.831        6.56E-03   5.11E-02   4660      PPP1R12B
  05205     Proteoglycans in cancer                       4.831        6.56E-03   5.11E-02   3479      IGF1
  05205     Proteoglycans in cancer                       4.831        6.56E-03   5.11E-02   1975      EIF4B
  05205     Proteoglycans in cancer                       4.831        6.56E-03   5.11E-02   2335      FN1
  03013     RNA transport                                 5.539        8.87E-03   6.53E-02   1975      EIF4B
  03013     RNA transport                                 5.539        8.87E-03   6.53E-02   8669      EIF3J
  03013     RNA transport                                 5.539        8.87E-03   6.53E-02   1965      EIF2S1
  03013     RNA transport                                 5.539        8.87E-03   6.53E-02   8661      EIF3A
  03013     RNA transport                                 5.539        8.87E-03   6.53E-02   4686      NCBP1

FDR, false discovery rate.

###### 

Downregulated genes by altered miRNA in AAN-UUC tissues.

  Path ID   Pathway name         Enrichment   P-value    FDR        Gene ID      Gene name
  --------- -------------------- ------------ ---------- ---------- ------------ ---------------
  05215     Prostate cancer      10.050       5.74E-15   1.21E-12   1871         E2F3
  05215     Prostate cancer      10.050       5.74E-15   1.21E-12   2260         FGFR1
  05215     Prostate cancer      10.050       5.74E-15   1.21E-12   2308         FOXO1
  05215     Prostate cancer      10.050       5.74E-15   1.21E-12   2932         GSK3B
  05215     Prostate cancer      10.050       5.74E-15   1.21E-12   3480         IGF1R
  05215     Prostate cancer      10.050       5.74E-15   1.21E-12   3551         IKBKB
  05215     Prostate cancer      10.050       5.74E-15   1.21E-12   367          AR
  05215     Prostate cancer      10.050       5.74E-15   1.21E-12   3845         KRAS
  05215     Prostate cancer      10.050       5.74E-15   1.21E-12   5156         PDGFRA
  05215     Prostate cancer      10.050       5.74E-15   1.21E-12   5594         MAPK1
  05215     Prostate cancer      10.050       5.74E-15   1.21E-12   5604         MAP2K1
  05215     Prostate cancer      10.050       5.74E-15   1.21E-12   64764        CREB3L2
  05215     Prostate cancer      10.050       5.74E-15   1.21E-12   6654         SOS1
  05215     Prostate cancer      10.050       5.74E-15   1.21E-12   6655         SOS2
  05215     Prostate cancer      10.050       5.74E-15   1.21E-12   6934         TCF7L2
  05215     Prostate cancer      10.050       5.74E-15   1.21E-12   7184         HSP90B1
  05215     Prostate cancer      10.050       5.74E-15   1.21E-12   8503         PIK3R3
  05215     Prostate cancer      10.050       5.74E-15   1.21E-12   1387         CREBBP
  05215     Prostate cancer      10.050       5.74E-15   1.21E-12   1869         E2F1
  05215     Prostate cancer      10.050       5.74E-15   1.21E-12   10000        AKT3
  05215     Prostate cancer      10.050       5.74E-15   1.21E-12   1385         CREB1
  04151     PI3K-Akt signaling   4.541        1.06E-13   1.11E-11   23678        SGK3
  04151     PI3K-Akt signaling   4.541        1.06E-13   1.11E-11   2932         GSK3B
  04151     PI3K-Akt signaling   4.541        1.06E-13   1.11E-11   3480         IGF1R
  04151     PI3K-Akt signaling   4.541        1.06E-13   1.11E-11   3551         IKBKB
  04151     PI3K-Akt signaling   4.541        1.06E-13   1.11E-11   3558         IL2
  04151     PI3K-Akt signaling   4.541        1.06E-13   1.11E-11   3696         ITGB8
  04151     PI3K-Akt signaling   4.541        1.06E-13   1.11E-11   5529         PPP2R5E
  04151     PI3K-Akt signaling   4.541        1.06E-13   1.11E-11   5586         PKN2
  04151     PI3K-Akt signaling   4.541        1.06E-13   1.11E-11   5594         MAPK1
  04151     PI3K-Akt signaling   4.541        1.06E-13   1.11E-11   5604         MAP2K1
  04151     PI3K-Akt signaling   4.541        1.06E-13   1.11E-11   5618         PRLR
  04151     PI3K-Akt signaling   4.541        1.06E-13   1.11E-11   5747         PTK2
  04151     PI3K-Akt signaling   4.541        1.06E-13   1.11E-11   59345        GNB4
  04151     PI3K-Akt signaling   4.541        1.06E-13   1.11E-11   6198         RPS6KB1
  04151     PI3K-Akt signaling   4.541        1.06E-13   1.11E-11   6256         RXRA
  04151     PI3K-Akt signaling   4.541        1.06E-13   1.11E-11   3845         KRAS
  04151     PI3K-Akt signaling   4.541        1.06E-13   1.11E-11   4254         KITLG
  04151     PI3K-Akt signaling   4.541        1.06E-13   1.11E-11   5156         PDGFRA
  04151     PI3K-Akt signaling   4.541        1.06E-13   1.11E-11   54541        DDIT4
  04151     PI3K-Akt signaling   4.541        1.06E-13   1.11E-11   672          BRCA1
  04151     PI3K-Akt signaling   4.541        1.06E-13   1.11E-11   7184         HSP90B1
  04151     PI3K-Akt signaling   4.541        1.06E-13   1.11E-11   7532         YWHAG
  04151     PI3K-Akt signaling   4.541        1.06E-13   1.11E-11   8503         PIK3R3
  04151     PI3K-Akt signaling   4.541        1.06E-13   1.11E-11   896          CCND3
  04151     PI3K-Akt signaling   4.541        1.06E-13   1.11E-11   2321         FLT1
  04151     PI3K-Akt signaling   4.541        1.06E-13   1.11E-11   10000        AKT3
  04151     PI3K-Akt signaling   4.541        1.06E-13   1.11E-11   10053-3105   C8orf-44-SGK3
  04151     PI3K-Akt signaling   4.541        1.06E-13   1.11E-11   1293         COL6A3
  04151     PI3K-Akt signaling   4.541        1.06E-13   1.11E-11   1385         CREB1
  04151     PI3K-Akt signaling   4.541        1.06E-13   1.11E-11   1977         EIF4E
  04151     PI3K-Akt signaling   4.541        1.06E-13   1.11E-11   2260         FGFR1
  04151     PI3K-Akt signaling   4.541        1.06E-13   1.11E-11   23035        PHLPP2
  04151     PI3K-Akt signaling   4.541        1.06E-13   1.11E-11   2309         FOXO3
  04151     PI3K-Akt signaling   4.541        1.06E-13   1.11E-11   6696         SPP1
  04151     PI3K-Akt signaling   4.541        1.06E-13   1.11E-11   64764        CREB3L2
  04151     PI3K-Akt signaling   4.541        1.06E-13   1.11E-11   6654         SOS1
  04151     PI3K-Akt signaling   4.541        1.06E-13   1.11E-11   6655         SOS2
  05200     Pathways in cancer   4.428        2.42E-12   1.70E-10   2122         MECOM
  05200     Pathways in cancer   4.428        2.42E-12   1.70E-10   2260         FGFR1
  05200     Pathways in cancer   4.428        2.42E-12   1.70E-10   2308         FOXO1
  05200     Pathways in cancer   4.428        2.42E-12   1.70E-10   25           ABL1
  05200     Pathways in cancer   4.428        2.42E-12   1.70E-10   2113         ETS1
  05200     Pathways in cancer   4.428        2.42E-12   1.70E-10   51684        SUFU
  05200     Pathways in cancer   4.428        2.42E-12   1.70E-10   5579         PRKCB
  05200     Pathways in cancer   4.428        2.42E-12   1.70E-10   5594         MAPK1
  05200     Pathways in cancer   4.428        2.42E-12   1.70E-10   5604         MAP2K1
  05200     Pathways in cancer   4.428        2.42E-12   1.70E-10   6934         TCF7L2
  05200     Pathways in cancer   4.428        2.42E-12   1.70E-10   7046         TGFBR1
  05200     Pathways in cancer   4.428        2.42E-12   1.70E-10   7184         HSP90B1
  05200     Pathways in cancer   4.428        2.42E-12   1.70E-10   7428         VHL
  05200     Pathways in cancer   4.428        2.42E-12   1.70E-10   7976         FZD3
  05200     Pathways in cancer   4.428        2.42E-12   1.70E-10   8503         PIK3R3
  05200     Pathways in cancer   4.428        2.42E-12   1.70E-10   862          RUNX1T1
  05200     Pathways in cancer   4.428        2.42E-12   1.70E-10   868          CBLB
  05200     Pathways in cancer   4.428        2.42E-12   1.70E-10   6655         SOS2
  05200     Pathways in cancer   4.428        2.42E-12   1.70E-10   5747         PTK2
  05200     Pathways in cancer   4.428        2.42E-12   1.70E-10   6256         RXRA
  05200     Pathways in cancer   4.428        2.42E-12   1.70E-10   6654         SOS1
  05200     Pathways in cancer   4.428        2.42E-12   1.70E-10   1869         E2F1
  05200     Pathways in cancer   4.428        2.42E-12   1.70E-10   3480         IGF1R
  05200     Pathways in cancer   4.428        2.42E-12   1.70E-10   10000        AKT3
  05200     Pathways in cancer   4.428        2.42E-12   1.70E-10   1387         CREBBP
  05200     Pathways in cancer   4.428        2.42E-12   1.70E-10   2932         GSK3B
  05200     Pathways in cancer   4.428        2.42E-12   1.70E-10   1871         E2F3
  05200     Pathways in cancer   4.428        2.42E-12   1.70E-10   5156         PDGFRA
  05200     Pathways in cancer   4.428        2.42E-12   1.70E-10   26060        APPL1
  05200     Pathways in cancer   4.428        2.42E-12   1.70E-10   367          AR
  05200     Pathways in cancer   4.428        2.42E-12   1.70E-10   324          APC
  05200     Pathways in cancer   4.428        2.42E-12   1.70E-10   4254         KITLG
  05200     Pathways in cancer   4.428        2.42E-12   1.70E-10   3551         IKBKB
  05200     Pathways in cancer   4.428        2.42E-12   1.70E-10   3845         KRAS

FDR, false discovery rate.

[^1]: Contributed equally
